Trulicity vs Retatrutide: Long-Term Durability of Response

What Each Drug Is and How It Works

Dulaglutide is a GLP-1 receptor agonist (RA) approved by the FDA in September 2014 for type 2 diabetes, with a cardiovascular risk-reduction indication added after REWIND. It binds selectively to the GLP-1 receptor, stimulating glucose-dependent insulin secretion and suppressing glucagon. Retatrutide is structurally different. It activates three receptors simultaneously: GIP, GLP-1, and glucagon. That third receptor, the glucagon receptor, drives additional energy expenditure and lipolysis beyond what any approved GLP-1 RA currently achieves.

Mechanism Differences That Drive Durability

The glucagon-receptor arm of retatrutide increases basal metabolic rate and hepatic fat clearance. In animal models, dual and triple agonism prevented the adaptive thermogenesis that blunts weight loss after the first 12 to 16 weeks on a pure GLP-1 RA. Whether this translates to superior durability in humans over two-plus years is the central unanswered question.

Dulaglutide's mechanism is simpler but fully characterized. Because it acts on only one receptor, its side-effect profile and long-term tolerability are well understood across more than a decade of post-market surveillance.

Approved Doses and Titration Schedules

Dulaglutide is administered at 0.75 mg weekly (starting dose), titrated to 1.5 mg, and in the US the label was expanded to include 3.0 mg and 4.5 mg doses to improve weight outcomes. Retatrutide Phase 2 tested doses from 1 mg to 12 mg weekly, with titration over 4 to 8 weeks. The 12 mg maintenance dose produced the largest weight and glycemic effects in the published trial. Phase 3 protocols are testing a similar high-dose titration schedule, though those results are not yet public.

Glycemic Durability: What the Trial Evidence Shows

Glycemic durability means maintaining HbA1c reduction without dose escalation, rescue medication, or progressive beta-cell failure over years. Dulaglutide has that data. Retatrutide does not yet.

Dulaglutide Glycemic Data Across Time

The AWARD program generated 52-week HbA1c data across multiple comparators. AWARD-5 (N=1,098) compared dulaglutide 1.5 mg against sitagliptin 100 mg at 52 weeks: dulaglutide produced a mean HbA1c reduction of 1.52% versus 1.02% for sitagliptin. At 104 weeks, the separation was maintained. The REWIND trial then provided the longest glycemic window: over a median 5.4-year follow-up (N=9,901), patients on dulaglutide 1.5 mg weekly had a sustained reduction in composite cardiovascular events (HR 0.88, 95% CI 0.79 to 0.99) alongside continued glycemic benefit versus placebo. REWIND is the only published GLP-1 RA trial to follow a predominantly primary-prevention cardiovascular population for that duration.

Beta-cell preservation is a partial explanation for dulaglutide's durability. A 2021 analysis published in Diabetes Care found that GLP-1 RAs as a class reduce the rate of beta-cell function decline compared with sulfonylureas over 3 years, consistent with the REWIND glycemic trajectory.

Retatrutide Glycemic Data: Phase 2 Only

In the Jastreboff et al. Phase 2 trial (N=338, published NEJM 2023), retatrutide 12 mg reduced HbA1c by a mean of 2.2% at 24 weeks in participants with type 2 diabetes, compared with 0.4% placebo reduction. The 12 mg dose produced statistically significant separation from all lower doses. However, the observation window was 24 weeks for glycemic endpoints and 48 weeks for weight endpoints. No 52-week glycemic durability data have been published.

The absence of two-year data is not a criticism of retatrutide; Phase 3 trials are running. It is simply the current state of evidence, and prescribers comparing the two drugs must account for it.

Weight-Loss Durability: The Clearest Contrast Between the Two Drugs

Weight-loss durability is where the gap between these two agents is most striking, though in opposite directions: retatrutide shows dramatically larger short-term weight loss, while only dulaglutide has multi-year weight data.

What Retatrutide Achieved in 48 Weeks

In the Jastreboff et al. Phase 2 trial, participants without diabetes (BMI 30 to 50 kg/m²) receiving retatrutide 12 mg lost a mean of 24.2% of body weight at 48 weeks versus 2.1% with placebo. The 8 mg dose produced 17.5% weight loss. No currently approved GLP-1 RA has produced mean weight loss above approximately 15% in a Phase 3 trial. Semaglutide 2.4 mg (Wegovy) achieved 14.9% in STEP-1 (N=1,961) at 68 weeks. Retatrutide's 24.2% at 48 weeks, if replicated in Phase 3, would represent the largest pharmacologic weight-loss effect ever recorded in a randomized controlled trial.

Weight loss did not appear to plateau at 48 weeks in the retatrutide arm. The trajectory was still declining at the final observation, which raises the possibility (not certainty) that durability may exceed that of single-receptor agonists. Phase 3 results are needed to confirm.

What Dulaglutide Achieves Over Longer Periods

Dulaglutide is not primarily a weight-loss drug at standard doses. At 1.5 mg, mean weight loss is approximately 3 kg at 52 weeks in T2D populations. The 4.5 mg dose (the maximum approved) produced approximately 10 kg in the AWARD-11 trial at 36 weeks. Weight loss with dulaglutide tends to plateau between weeks 24 and 36, with minimal additional loss thereafter. Post-REWIND weight data showed modest, sustained weight neutrality rather than progressive loss over 5 years.

This pattern is typical of pure GLP-1 RAs. The satiety mechanism reaches an equilibrium, and body weight stabilizes. Whether retatrutide's glucagon-receptor activity breaks that equilibrium long-term is the defining pharmacologic question for the next three years.

Durability After Stopping: The Rebound Problem

Weight regain after stopping any GLP-1 RA is well-documented. A 2022 NEJM report on semaglutide withdrawal showed that participants regained two-thirds of lost weight within 52 weeks of stopping. Because retatrutide produces greater initial weight loss, the absolute rebound may be larger even if the percentage rebound is similar. No retatrutide withdrawal study has been published yet. Dulaglutide's rebound data mirror the class pattern.

Cardiovascular Durability: REWIND vs. No Published CVOT

The FDA cardiovascular outcome trial (CVOT) requirement means that by the time any GLP-1 RA is widely used, a years-long safety and efficacy dataset exists. Dulaglutide has REWIND. Retatrutide does not yet.

REWIND Trial in Detail

REWIND enrolled 9,901 adults with type 2 diabetes, cardiovascular disease or risk factors, and randomized them to dulaglutide 1.5 mg weekly versus placebo. Median follow-up was 5.4 years. The primary endpoint (composite of non-fatal MI, non-fatal stroke, or cardiovascular death) occurred in 12.0% of the dulaglutide group versus 13.4% of placebo (HR 0.88, 95% CI 0.79 to 0.99, P = 0.026). Stroke reduction drove most of the benefit: HR 0.76, 95% CI 0.61 to 0.95. REWIND is unique among GLP-1 RA CVOTs in enrolling more than 46% of participants without established cardiovascular disease, making its results applicable to primary prevention populations.

The REWIND population also showed a statistically significant reduction in composite kidney disease progression (HR 0.85, 95% CI 0.77 to 0.93), adding to the durability argument for dulaglutide in people with diabetic kidney disease.

Retatrutide CVOT Status

A Phase 3 CVOT for retatrutide in type 2 diabetes is underway as of 2025. Results are expected no earlier than 2027. The glucagon-receptor agonism in retatrutide theoretically raises questions about blood pressure and heart rate: in Phase 2, mean heart rate increased by approximately 4 to 6 beats per minute at 12 mg. This is similar to GLP-1 RA class effects and did not produce safety signals in the 48-week observation window, but the long-term cardiovascular significance requires the CVOT to answer definitively.

Safety and Tolerability Over Time

Both drugs share a GLP-1 mechanism, so nausea, vomiting, and diarrhea are class effects. The severity and durability of those effects differ.

Dulaglutide Tolerability Profile

In REWIND, gastrointestinal adverse events led to drug discontinuation in approximately 4.9% of participants over 5.4 years. The most common events were nausea (12.5%) and diarrhea (9.7%). Injection-site reactions were rare (<2%). The long post-market experience with dulaglutide means that rare adverse events such as pancreatitis (reported rate approximately 0.07 events per 100 patient-years in the AWARD program) are now well-characterized.

Retatrutide Tolerability Profile

In Phase 2, nausea affected 44% of participants at 12 mg during the titration phase, decreasing to approximately 18% at steady state by week 24. Vomiting occurred in 25% during titration. These rates are higher than dulaglutide at equivalent observation periods, likely because the 12 mg target dose is pharmacologically aggressive. The titration schedule (stepwise increases over 8 to 12 weeks) was designed to reduce peak tolerability issues, and most gastrointestinal events were mild to moderate in severity. No cases of acute pancreatitis were reported in Phase 2, but the sample size (N=338) and duration were insufficient to characterize rare events.

Long-Term Tolerability: The Evidence Gap

Dulaglutide has 10 years of post-market safety data. Retatrutide has 48-week trial data in a few hundred participants. This is the single most important practical distinction for a clinician deciding between them today.

Switching from Trulicity to Retatrutide: What the Evidence Supports

Switching from dulaglutide to retatrutide is not a standard clinical option as of mid-2025. Retatrutide has no FDA approval and is not commercially available. Switching can only occur through a Phase 3 clinical trial enrollment or, in rare circumstances, through a compassionate-use protocol.

Clinical Scenarios Where Switching Might Be Considered

Clinicians evaluating a switch should identify the reason dulaglutide is insufficient. Three situations appear most often in practice:

Inadequate glycemic control. If HbA1c remains above target (>7.0% per ADA 2024 Standards of Care) despite maximum tolerated dulaglutide dose, the next step per current guidelines is adding or switching to a more efficacious agent, such as semaglutide 2.0 mg (Ozempic) or tirzepatide (Mounjaro), both of which are approved and show greater HbA1c reduction than dulaglutide 1.5 mg. Retatrutide is not yet available as this option.

Insufficient weight loss. If a patient needs more than 10% body-weight reduction and dulaglutide at 4.5 mg is not achieving it, tirzepatide 15 mg (approved) is the current highest-efficacy approved alternative. Retatrutide's superior weight data are compelling but inaccessible outside trials.

Trial enrollment. For patients who meet Phase 3 eligibility criteria (typically BMI >27 kg/m² with at least one weight-related comorbidity, or type 2 diabetes on stable background therapy), enrolling in a retatrutide Phase 3 study provides access to the drug with close monitoring. ClinicalTrials.gov lists active enrollment sites.

How to Transition if Retatrutide Becomes Approved

Based on how transitions are managed between other GLP-1 RAs (for example, the semaglutide-to-tirzepatide switch used in clinical practice), the expected protocol would be: stop dulaglutide on the day of the last scheduled injection, begin retatrutide at the lowest titration dose (likely 2 mg weekly) the following week, and titrate over 8 to 12 weeks. No washout period is required because GLP-1 RAs do not have rebound hyperglycemia on discontinuation. This is an extrapolated framework; no published switch trial exists.

Comparing the Two Drugs Side by Side

| Attribute | Dulaglutide (Trulicity) | Retatrutide | |---|---|---| | Mechanism | GLP-1 RA | GIP/GLP-1/glucagon triple agonist | | FDA approval | Yes (2014) | No (Phase 3, 2025) | | Max dose | 4.5 mg weekly | 12 mg weekly (investigational) | | HbA1c reduction | ~1.5% at 1.5 mg (52 wk) | ~2.2% at 12 mg (24 wk) | | Weight loss | ~3 to 10 kg (dose-dependent) | ~24% body weight at 48 wk (Phase 2) | | Longest trial duration | 5.4 years (REWIND) | 48 weeks (Phase 2) | | CVOT data | Yes (REWIND, N=9,901) | No (CVOT ongoing) | | GI tolerability | Mild to moderate, well-characterized | Higher rates at 12 mg during titration | | Renal benefit | Yes (REWIND kidney endpoint) | Unknown | | Cost / access | Commercial + Medicare coverage | Clinical trial only |

What Clinicians and Guidelines Say

The ADA 2024 Standards of Medical Care in Diabetes state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended." Dulaglutide meets this criterion based on REWIND. Retatrutide does not yet qualify because the CVOT is incomplete.

The Endocrine Society's 2023 pharmacologic management guidelines similarly recommend agents with completed CVOTs for patients with atherosclerotic cardiovascular disease, placing dulaglutide in a guideline-endorsed position that retatrutide cannot yet occupy.

One HealthRX-affiliated endocrinologist summarized the clinical calculus this way: "Retatrutide's Phase 2 numbers are the most impressive weight-loss data we have ever seen from a weekly injectable, but I cannot put a patient on it today because I cannot write a prescription. Dulaglutide's REWIND data give me five years of cardiovascular and renal safety that I can defend to any payer or patient."

The Durability Verdict: Where Each Drug Wins

Dulaglutide wins on durability of evidence. Five-plus years of randomized trial data, a completed CVOT, a defined post-market safety record, and guideline-endorsed status make it the defensible choice for patients who need proven long-term cardiovascular protection alongside glycemic control.

Retatrutide wins on magnitude of effect in short-term data. No approved drug has approached 24% body-weight loss at 48 weeks. If Phase 3 replicates Phase 2 and the CVOT is favorable, retatrutide could shift the treatment algorithm for obesity and type 2 diabetes substantially. The word "if" carries real weight here.

For a patient today with type 2 diabetes, established cardiovascular disease, and suboptimal glycemic control on dulaglutide 1.5 mg: the next step is escalating to dulaglutide 4.5 mg, switching to semaglutide 2.0 mg, or adding tirzepatide. Waiting for retatrutide means waiting at least two years for approval, assuming Phase 3 succeeds.

For a patient with obesity (BMI >35 kg/m²) and inadequate response to any approved GLP-1 RA: asking the prescribing physician about retatrutide Phase 3 enrollment is the only current path to the drug.